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ABSTRACT
Introduction: The fluocinolone acetonide (FA)
intravitreal implant 0.59 mg (Retisert,
Bausch ? Lomb, Rochester, NY, USA) provides
sustained release of FA directly to the vitreous
cavity over a prolonged period of time. The
purpose of this study was to evaluate the safety
and efficacy of a 0.59- and 2.1-mg FA
intravitreal implant in patients with
noninfectious posterior uveitis.
Methods: A prospective, multicenter,
randomized, double-masked, dose-controlled
study was performed. Patients were
randomized to the 0.59- or 2.1-mg FA implant
surgically placed in the vitreous cavity through
a pars plana incision and were evaluated at visits
through 3 years. Patients with bilateral disease
had the more severely affected eye implanted.
Outcomes included uveitis recurrence rate, best-
corrected visual acuity (BCVA), use of
adjunctive therapy, and safety.
Results: A total of 239 patients, predominantly
Asian, were implanted (n = 117, 0.59-mg
implant; n = 122, 2.1-mg implant).
Approximately 80% of patients had bilateral
disease. Recurrence rates for implanted eyes
decreased from 42.3% during the 1-year pre-
implantation period to 25.9% during the 3-year
post-implantation period (P = 0.0003) and
increased for nonimplanted fellow eyes from
19.8 to 59.7% (P\0.0001). More implanted
eyes gained C3 lines of BCVA compared to
nonimplanted fellow eyes (P B 0.0046); and
implanted eyes required less adjunctive systemic
therapy and fewer periocular injections
(P\0.0001). Elevations of intraocular pressure
(C10 mm Hg) were frequent in implanted eyes
(67.8%, 0.59-mg implant; 71.3%, 2.1-mg
implant); nearly all (94.9%) phakic implanted
eyes required cataract surgery.
Trial Registration Clinical Trials. gov #NCT0456482.
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Conclusion: The FA intravitreal implant
significantly reduced uveitis recurrence rates
and led to improvements in visual acuity and
reductions in adjunctive therapy. Lens clarity
and intraocular pressure require monitoring.
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INTRODUCTION
The term ‘uveitis’ comprises a group of
intraocular inflammatory conditions that
directly or indirectly affects the iris, ciliary
body, and choroid, collectively known as the
uveal tract, as well as the retina, optic nerve,
and vitreous [1–4]. In most cases, the etiology of
uveitis is unknown; however, it can be
associated with autoimmune disease, infection
(viral, fungal, or parasitic), or trauma [2–6].
Uveitis results in significant visual impairment
and is thought to account for 10–15% of all
cases of total blindness in the United States (US)
and developed world [1, 4, 6–8]. While posterior
uveitis accounts for only 20% of the estimated 1
in 500 people in the US with uveitis [1], it is the
more severe form of the disease.
The primary causes of vision loss in patients
with uveitis are cystoid macular edema (CME)
and/or cataract [1, 4, 7], with CME being the
leading cause of vision loss in posterior uveitis.
Treatments aimed at reducing CME are
therefore effective in the treatment of uveitis.
Corticosteroids are considered the mainstay of
noninfectious uveitis treatment [4, 9]. However,
since the disease is typically chronic in nature,
patients often require long-term repeated
treatment with either topical or systemic
corticosteroids [10, 11]. In severe cases of
uveitis, multiple rounds of sub-Tenon or
intravitreal corticosteroid injections as well as
systemic corticosteroids may be necessary. The
potential for complications such as
endophthalmitis, vitreous hemorrhage, and
retinal detachment following use of repeated
intravitreal injections is substantial [12, 13].
Systemic corticosteroids require high dosages to
achieve therapeutic concentrations in the eye
and are associated with systemic side effects
including hypertension, hyperglycemia, and
increased susceptibility to infection [14, 15].
Immunosuppressive agents can be an effective
treatment option, but are associated with
serious and potentially life-threatening
systemic adverse events (AEs) such as renal
and hepatic failure and bone marrow
suppression [9, 16]. Thus, such therapy is
usually reserved for patients with severe uveitis
who are unresponsive to corticosteroid therapy
or with corticosteroid-induced complications.
The fluocinolone acetonide (FA) intravitreal
implant 0.59 mg (Retisert, Bausch ? Lomb,
Rochester, NY, USA) was developed to provide
sustained release of a corticosteroid directly to
the vitreous cavity over a prolonged period of
time, thus avoiding complications with
systemic therapy as well as those associated
with repeated corticosteroid injections.
Approved by the US Food and Drug
Administration for the treatment of chronic
non-infectious posterior uveitis (NIPU), the FA
implant is inserted into the posterior segment
through a small pars plana incision and sutured
to the sclera. The implant releases FA at a
nominal initial rate of 0.6 lg/day, decreasing
over the first month to a steady state between
0.3 and 0.4 lg/day for approximately 2.5 years.
The sustained release of FA was previously
reported to result in long-term, continuous
control of inflammation [17, 18], and the
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implant is therefore considered to be
particularly suitable for patients with chronic
inflammation due to NIPU.
The FA intravitreal implant was evaluated in
three large multicenter clinical trials during the
course of its development. Thirty-four-week [19]
and 3-year results [18] of the first trial and
2-year results [20] of the second trial have been
published previously. Both of these trials were
conducted in predominantly non-Asian
patients. Herein, we report the results of the
third trial which evaluated the safety and
efficacy of the 0.59-mg implant (marketed
formulation) and a 2.1-mg FA implant in a
predominantly Asian population with chronic,
recurrent, unilateral or bilateral NIPU.
METHODS
Study Design
This was a 3-year multicenter, randomized,
double-masked, dose-controlled safety and
efficacy study of two FA intravitreal implants—
one containing 0.59 mg and the other 2.1 mg—
in patients with chronic, recurrent, unilateral or
Table 1 Patient inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Males or non-pregnant females C6 years Allergy to FA or any component of the delivery system
One or both eyes must have History of iritis only; no vitreous cells or haze
History of recurrent NIPU of C1 year requiring either Infectious uveitis or vitreous hemorrhage
Systemic steroid therapy/equivalent for C3 months, or Toxoplasmosis scar/retinal detachment
C 2 sub-Tenon steroid injections during the 6 months
prior to enrollment, or
Ocular media opacity
C2 recurrences that require systemic or sub-Tenon
injection steroid therapy within the 6 months prior to
enrollment
History/presence of uncontrolled IOP while receiving
steroid therapy resulting in vision loss, or IOP[25 mm Hg
requiring C2 anti-glaucoma medications
The eye randomized to undergo implantation must have had Ocular surgery within 3 months of enrollment
B10 anterior chamber cells and vitreous haze less than
grade 2 (treatment to attain these criteria was allowed)
Need for chronic systemic steroids ([15 mg prednisolone/
day) or systemic immunosuppressive therapy for nonocular
disease
Visual acuity of C1.4 logMAR in the implanted eye Positive HIV test
Ability to understand and sign the informed consent form Patients for whom risk outweighs study beneﬁts according to
the physician
Current enrollment in another study or participation within
1 month before entry into this study
FA ﬂuocinolone acetonide, HIV human immunodeﬁciency virus, IOP intraocular pressure, logMAR logarithm of the
minimum angle resolution, NIPU noninfectious posterior segment uveitis
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bilateral NIPU (ClinicalTrials.gov identifier:
NCT0456482). Patient inclusion and exclusion
criteria are presented in Table 1. The study was
conducted at 19 sites in the following countries:
India (3), Canada (5), Australia (4), US (4), Hong
Kong (1), and the Philippines (2); the study
received Institutional Review Board approval at
each center. Before study entry and providing
written informed consent, each patient received
a full explanation of study procedures. An
independent Data Safety Monitoring Board
assessed the safety and efficacy data as the
study progressed and alerted the sponsor if any
issues arose. All procedures followed were in
accordance with the ethical standards of the
responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1975, as
revised in 2000.
All patients were randomized 1:1 via a
computer-generated randomization procedure
to receive one of the two FA implant doses (0.59
or 2.1 mg) in their study eye. Patients were
stratified according to the investigative site and
method of NIPU management history [(1)
systemic corticosteroids or immunosuppressive
agents and (2) periocular injection of
corticosteroids] before treatment group
assignment. Patients with unilateral disease
received the implant in the affected eye. In
patients with bilateral disease, the more severely
affected eye underwent implantation. Criteria
for determining which eye was more severely
affected included (1) an increased number of
recurrences of NIPU during the 1-year pre-
implantation period or, if both eyes had
similar recurrences, (2) an increase in therapy
during the 1-year pre-implantation period or, if
both eyes had similar therapy, (3) a greater
degree of visual acuity impairment or, if both
eyes had similar visual acuity, (4) the judgment
of the physician. Implanted eyes were
designated as ‘study eyes’, while nonimplanted
eyes were designated as ‘fellow eyes’. Patients
with bilateral disease were considered for
inclusion in the study only if the investigator
felt that it would be possible to control the
fellow-eye ocular inflammation with local
therapy.
The FA implants and surgical implantation
procedure have been described in detail
elsewhere [11, 18, 19]. Briefly, the polymer-
based intravitreal implant contains a sustained-
release formulation of a 0.59- or 2.1-mg FA
tablet 1.5 mm in thickness encased in a silicone
elastomer cup that is attached to a heat-cured
polyvinyl alcohol suture tab. The 0.59-mg
implant releases FA at approximately 0.4 lg/
day, whereas the 2.1-mg implant releases FA at a
rate of approximately 2 lg/day initially,
decreasing to approximately 1 lg/day over a
3-year period. Surgical implantation was
performed under local or general anesthesia
with placement of the implant in the
inferonasal or inferotemporal quadrant of the
posterior segment at the pars plana. A pars
plana infusion line was placed to reduce the
possibility of globe collapse in vitrectomized
eyes. An 8-0 ProleneTM (Ethicon, Inc.,
Somerville, NJ, USA) suture anchored the
implant, such that the top surface of the
implant faced the front of the eye.
One week post-implantation, patients
discontinued use of existing therapy for ocular
inflammation as follows: (1) those receiving oral
corticosteroids reduced their use over at least
6 weeks by approximately 30% per week until
the dose reached 2.5 mg/day for 1 week before
completely discontinuing systemic treatment;
(2) those receiving topical corticosteroids
gradually tapered the dosage from hourly use
to once-per-day use for 1 week before
completely discontinuing systemic treatment;
and (3) those receiving immunosuppressive
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therapy gradually tapered the dosage over a
6-week period at the investigator’s discretion.
Patients were evaluated on day 2 and at weeks 1,
4, 8, 12, 18, 24, 30, 34, and 52. After the 1-year
visit, follow-up evaluation visits were
conducted at 3-month intervals for an
additional 2 years. Evaluations, also described
previously [18], included best-corrected visual
acuity (BCVA), applanation tonometry, slitlamp
biomicroscopy, indirect ophthalmoscopy,
automated visual field testing (Humphrey
24–2), hematology, and serum chemistry
testing. Optical coherence tomography was
not widely available at the time this study was
conducted; consequently, patients were
evaluated with fluorescein angiography at
screening, at week 8, week 34, and 1, 2, and
3 years using a standardized protocol with
macular hyperfluorescence evaluated by
masked readers as described previously [19].
Efficacy Outcomes
Three types of comparisons were utilized in the
study: (1) a comparison of post-implantation
findings to retrospective findings recorded
during the 1-year pre-implantation period, (2)
a dose comparison in terms of both efficacy and
safety, and (3) a within-patient comparison of
implanted eyes and nonimplanted fellow eyes
in patients with bilateral disease.
The primary efficacy outcome was the
change in uveitis recurrence rate in the
implanted eye (during the 1-year period pre-
implantation versus 3 years post-implantation).
Based on medical chart review, investigators
recorded whether an episode during the 1-year
pre-implantation period met the protocol
definition of a post-implantation recurrence. A
pre-implantation recurrence with (1) a
maximum anterior chamber (AC) cell score\2;
(2) a maximum vitreous haze score\2; and (3) a
maximum reduction in visual acuity of\0.30
logarithm of the minimum angle resolution
(logMAR) or Snellen equivalent was not
considered sufficiently severe to be counted in
this analysis. If the medical chart lacked
sufficient detail to determine whether the pre-
implantation recurrence met the protocol
definition, no pre-implantation recurrence was
recorded for this analysis. Recurrence within the
3-year post-implantation period was defined as
follows: (1) a C2-step increase compared to
baseline in the number of AC cells not
attributable to any condition other than NIPU,
(2) a C2-step increase compared to baseline in
vitreous haze not attributable to any condition
other than NIPU, or (3) a deterioration in BCVA
from baseline of at least 0.30 logMAR not
attributable to any condition other than NIPU.
Recurrences were considered ‘observed’ when
they were seen and recorded by study
investigators, whereas they were considered
‘imputed’ when a subject was not seen within
10 weeks of the final scheduled visit.
Secondary efficacy outcomes were evaluated
using the fellow nonimplanted eye as a control
for the study eye and included: rate of and time to
post-implantation recurrence of uveitis; change
in BCVA; and area of CME using a 300-s
fluorescein angiogram, and the proportion of
eyes requiring systemic therapy or periocular
injections to control inflammation using the
pre-implantation comparison group data.
Secondary efficacy outcomes included observed
and imputed recurrence data where applicable.
Safety Outcomes
Safety outcomes included intraocular pressure
(IOP), lens opacity estimated using the lens
opacity classification system (LOCS) II, visual
field, ocular and nonocular AEs, visual acuity,
and ophthalmoscopic examination findings.
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Ocular AEs were defined as any unexpected
ocular condition that was considered by the
investigator to be clinically significant including
but not limited to: (1) any IOP increase requiring
medication or increased dosage/frequency, (2)
any IOP[30 mm Hg 3 months post-surgery, (3)
any IOP\6 mmHg, (4) any loss of C3 lines visual
acuity from baseline or last scheduled visit, and
(5) retinal tear.
Statistical Analyses
Statistical analyses were performed using SAS,
version 8.2 (SAS Institute, Cary, NC, USA). The
McNemar test for correlated proportions was
used to analyze the primary and secondary
efficacy end points. Time to uveitis recurrence
was determined via Kaplan–Meier analysis. The
Cochran–Mantel–Haenzsel v2 test was used for
between-dose comparison of the frequency of
uveitis recurrence post-implantation. Statistical
analyses of safety variables were performed
using the v2 test (observations were stratified
according to the investigative site and the
therapy used during the pre-implantation
period). Distribution of time to first IOP
elevation of C10 mm Hg was analyzed via
proportional hazards regression, with
Table 2 Patient baseline demographic characteristics
Parameter Treatment group* All N5 239
0.59-mg n5 117 2.1-mg n5 122
Age (years)
Mean (standard deviation) 42.5 (14.1) 40.4 (12.5) 41.4 (13.3)
Range (min–max) 12.0–74.0 15.0–92.0 12.0–92.0
Race, n (%)
Caucasian 24 (20.5) 28 (23.0) 52 (21.8)
African American 3 (2.6) 4 (3.3) 7 (2.9)
Asian 83 (70.9) 84 (68.9) 167 (69.9)
Hispanic 2 (1.7) 2 (1.6) 4 (1.7)
Other 5 (4.3) 4 (3.3) 9 (3.8)
Gender, n (%)
Male 47 (40.2) 58 (47.5) 105 (43.9)
Female 70 (59.8) 64 (52.5) 134 (56.1)
Laterality of uveitis, n (%)
Unilateral 23 (19.7) 24 (19.7) 47 (19.7)
Bilateral 94 (80.3) 98 (80.3) 192 (80.3)
Previous uveitis treatment, n (%)
Systemic 89 (76.1) 87 (71.3) 176 (73.6)
Local 28 (23.9) 35 (28.7) 63 (26.4)
* P[0.05 for all comparisons of baseline characteristics between treatment groups (analysis of variance for continuous
variables; v2 test for categorical variables)
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observations also stratified according to
investigative site and therapy used during the
pre-implantation period. Adverse events were
compared using the Fisher’s exact test.
Descriptive statistics were calculated in all
analyses and performed on the intent-to-treat
population, which was defined as all enrolled
patients who received implants and attended at
least one post-implantation visit.
RESULTS
Enrollment for this study began in May 2002,
and the last 3-year visit occurred in April 2006.
A total of 239 patients were randomized to
receive the 0.59-mg (n = 117) or the 2.1-mg
(n = 122) FA intravitreal implant. Although it
was planned to include 250 patients,
enrollment was suspended at 239 due to the
severe acute respiratory syndrome epidemic in
Asia and Canada. Table 2 summarizes the
patient demographic characteristics. Most
patients were in the fifth decade of life, and
the majority were Asian. Approximately 80%
(192/239) of patients had bilateral disease, and
73.6% (176/239) were using systemic
immunomodulatory therapy for control of
uveitis upon enrollment. There were no
significant differences in baseline
characteristics between treatment groups
(P C 0.2213). The majority of cases (178/239)
had an idiopathic etiology. The most
commonly known etiologies were Vogt–
Koyanagi–Harada and Behc¸et’s disease
representing 24 and 14 cases, respectively.
A total of 211 patients (88.3%) completed
the study. Twenty-eight patients (11.7%) did
not complete the study: 11 patients (9.4%) from
the 0.59-mg implant group and 17 patients
(13.9%) from the 2.1-mg implant group. The
most common reason for withdrawal (in both
dose groups combined) was the occurrence of
an AE. Adverse events, all resulting in
explantation, were cited as the reason for
withdrawal in 17 patients (n = 4, 0.59-mg
implant; n = 13, 2.1-mg implant). Other
reasons for withdrawal included loss to follow-
up (n = 3, 0.59-mg implant; n = 1, 2.1-mg
implant), death (n = 1, 0.59-mg implant;
n = 2, 2.1-mg implant), subject condition no
Table 3 Uveitis recurrence rates in implanted eyes pre- and post-implantation






1-year pre-implantation 51 (43.6) 50 (41.0) 101 (42.3)
























P values were calculated via the McNemar test
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longer requiring study drug (n = 1, 2.1-mg
implant), protocol violation (n = 1, 0.59-mg
implant), withdrawal of consent (n = 1, 0.59-
mg implant), and administrative problems
(n = 1, 0.59-mg implant).
Uveitis Recurrence Rates
Uveitis recurrence rates for implanted eyes are
shown in Table 3. Recurrence rates in eyes
treated with the 0.59-mg implant decreased
significantly from the 1-year pre-implantation
period to the 1-, 2-, and 3-year post-
implantation period (P\0.0001 for all).
Recurrence rates for eyes treated with the 2.1-
mg implant were significantly decreased from
the pre-implantation rate at the 1- and 2- year
post-implantation period, but not at the 3-year
post-implantation period consistent with
in vitro drug release data indicating that the
2.1-mg implant was depleted of FA earlier than
the 0.59-mg implant. In contrast, the uveitis
recurrence rate in nonimplanted fellow eyes
(both dose groups combined) increased from
19.8% (47/238 eyes) during the 1-year pre-
implantation period to 49.6% (118/238),
57.6% (137/238), and 59.7% (142/238), at the
1-, 2-, and 3-year post-implantation period,
respectively (P\0.0001 versus the pre-
implantation period). Fellow eye recurrence
rates in the 0.59- and the 2.1-mg FA implant
groups were similar. Results of the analysis of
the difference between pre- and post-
implantation recurrence rates for implanted
study eyes and nonimplanted fellow eyes at 3
years including imputed data were consistent
with those based on observed recurrence rates
with the exception of the imputed 3-year post-
implantation recurrence rate for all implanted
study eyes (combined dose groups) which was
not significantly lower than the pre-
implantation recurrence rate.
Further within-subject comparison of the
uveitis recurrence rate (imputed) at the 3-year
follow-up period in implanted eyes vs those of
nonimplanted eyes showed that the recurrence
rate was significantly lower in implanted eyes
compared to nonimplanted eyes for both dose
groups and the combined dose group
(P\0.0001 for all).
Time to Uveitis Recurrence
Kaplan–Meier analysis was used to evaluate
time to recurrence of uveitis for implanted and
nonimplanted eyes (Fig. 1). The difference in
time to recurrence of uveitis in implanted
versus nonimplanted eyes was statistically
significant for both dose groups (P\0.0001).
Recurrences for fellow nonimplanted eyes
occurred much earlier than recurrences for
implanted eyes. In the 0.59-mg FA implant
group, uveitis recurrence in nonimplanted
fellow eyes increased rapidly during the first
150 days after implantation of the contralateral
eye, whereas for implanted eyes, a significant
increase in uveitis recurrence was not seen until
Fig. 1 Kaplan–Meier time to uveitis recurrence for
implanted study eyes versus nonimplanted fellow eyes in
the 0.59- and 2.1-mg implant group. Discontinued patients
were censored following their last visit. P\0.001 for the
within-treatment difference comparison of study eye versus
fellow eye; P = 0.0062 for the between-treatment differ-
ence in implanted eyes
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approximately 1,000 days after implantation
(P\0.0001). Similar results were observed in
the 2.1-mg implant group, although a trend
toward recurrence of uveitis in the 2.1-mg
group was observed beginning at
approximately 24 months.
Further Kaplan–Meier analysis of the
freedom from recurrence of uveitis comparing
implanted eyes in the 0.59- and 2.1-mg group
showed that the difference between doses was
significant [hazard ratio of 1.97 (95% CI
1.21–3.21); P = 0.0062]. Recurrence began
earlier for study eyes in the 2.1-mg FA implant
group, at approximately 24 months, compared
to the 0.59-mg FA implant dose. Again, these
results were not unexpected based on known
in vitro drug release data.
Kaplan–Meier analysis of implanted study
eyes versus nonimplanted fellow eyes
performed only for patients with bilateral
disease yielded similar results: the time to
recurrence of uveitis was significantly longer
in implanted eyes than in fellow nonimplated
eyes (P\0.0001, data not shown).
Adjunctive Therapy
The FA intravitreal implant reduced the need
for adjunctive uveitis treatment. The proportion
of patients requiring adjunctive treatment to
control inflammation before and after FA
implantation is shown in Table 4. The
proportion of patients requiring adjunctive
systemic therapy decreased by an approximate
80% in the 3-year post-implantation compared
to the 1-year pre-implantation period regardless
of FA implant dosage. The proportion of eyes
requiring adjunctive periocular injections or
topical steroids was reduced by approximately
80% in eyes receiving the 0.59-mg FA implant
and 60% and 50%, respectively, in eyes
receiving the 2.1-mg FA implant during the
3-year implantation period compared to the
1-year pre-implantation period. In contrast, the
proportion of nonimplanted fellow eyes
requiring periocular injections or topical
steroids in the 3-year post-implantation period
increased or remained similar to the pre-
implantation period.
Visual Acuity
Mean changes in BCVA from baseline up to
3 years post-implantation in the 0.59- and 2.1-
mg implant groups are presented in Fig. 2. The
mean change from baseline in logMAR BCVA at
2 years (-0.153) and 3 years (-0.141) post-
implantation in implanted eyes (0.59-mg
group) was significant (P B 0.0007).
In the 0.59-mg group, 2.1-mg group, and
combined dose group at the 3-year visit, 31.1%
(33/106), 23.6% (25/106), and 27.4% (58/212)
of implanted eyes, respectively, improved by C3
lines over baseline compared to 7.6% (8/105),
11.4% (12/105), and 9.5% (20/210) of
nonimplanted eyes (P B 0.0046 for the
difference in each dose group). In contrast,
there was no significant difference between
implanted eyes (both doses) and fellow
nonimplanted eyes in the proportion of eyes
that lost C3 lines of BCVA from baseline at the
3-year visit (Fig. 3). Most instances of C3 line
loss in BCVA of implanted eyes occurred during
the immediate postoperative period. Loss of C3
lines in BCVA was also often observed between
12 and 21 months post-implantation when
cataracts were most prevalent. At the 3-year
follow-up visit, 9.4% (10/116) of implanted eyes
in the 0.59-mg FA implant group had a loss
of C3 lines of BCVA compared to 17.0% (18/
106) of implanted eyes in the 2.1-mg implant
group.
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Cystoid Macular Edema
The mean area of CME measured on the 300-s
fluorescein angiogram decreased from
38.0 mm2 at screening to 9.3 mm2 at the
34-week post-implantation visit in eyes that
received the 0.59-mg implant. For the
remainder of the 3-year post-implantation
follow-up period in the 0.59-mg FA implant
group, mean area of CME for implanted eyes
continued to decrease to a mean 3-year CME
area of 6.2 or 4.6 mm2 using the last observation
carried forward (LOCF). Eyes receiving the 2.1-
mg implant experienced a reduction in the area
of CME from 46.1 mm2 at screening to 4.7 mm2
at the 34-week post-implantation visit;
however, this increased to 15.3 mm2 by the
3-year visit (LOCF mean CME was 12.8 mm2). In
nonimplanted fellow eyes for both dose groups
combined, the mean area of CME fluctuated
Table 4 Use of adjunctive therapy








0.59 mg 117 74 (63.2) 16 (13.9) 14 (12.0) \0.0001
2.1 mg 122 72 (59.0) 11 (9.2) 16 (13.1) \0.0001
All 239 146 (61.1) 27 (11.5) 30 (12.6) \0.0001
Periocular injections, study eyeb
0.59 mg 117 65 (55.6) 8 (6.8) 11 (9.4) \0.0001
2.1 mg 122 76 (62.3) 8 (6.6) 30 (24.6) \0.0001
All 239 141 (59.0) 16 (6.7) 41 (17.2) \0.0001
Periocular injections, fellow eyeb
0.59 mg 117 26 (22.2) 46 (39.3) 56 (47.9) \0.0001
2.1 mg 121 31 (25.6) 42 (34.7) 55 (45.5) 0.0001
All 238 57 (23.9) 88 (37.0) 111 (46.6) \0.0001
Topical corticosteroids, study eyea
0.59 mg 117 47 (40.2) 11 (9.6) 9 (7.7) \0.0001
2.1 mg 122 50 (41.0) 6 (5.0) 25 (20.5) 0.0079
All 239 97 (40.6) 17 (7.2) 34 (14.2) \0.0001
Topical corticosteroids, fellow eyea
0.59 mg 117 28 (23.9) 37 (32.2) 25 (21.4) 0.7055
2.1 mg 121 32 (26.4) 36 (30.3) 35 (28.9) 0.3035
All 238 60 (25.2) 73 (31.2) 60 (25.2) 0.6115
a Comparisons were made at the baseline visit and at the 1- and 3-year visits
b Comparisons were made during the entire 1-year pre-implantation period and the 1- and 3-year post-implantation
periods. One fellow eye (2.1-mg FA implant group) was prosthetic, and thus the sample size for fellow eyes was 238)
c P value for 1 year pre-implantation data compared with 3 year postimplantation data
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within a narrow range over the 3-year post-
implantation follow-up period and the area of
CME at screening was very similar to that at the
3-year visit (approximately 15–20 mm2). The
number of patients experiencing any reduction
in the area of CME between baseline and 3-year
post-implantation is presented in Table 5.
Safety Outcomes
Mean (±SD) exposure to FA was 1,038.9 (188.0)
days in the 0.59-mg implant group and 1,016.1
(225.1) days in the 2.1-mg implant group.
Treatment-emergent ocular AEs (including
perioperative events) were reported in 99.6%
(238/239) of implanted study eyes and in 81.6%
(195/239) of fellow nonimplanted eyes. Table 6
presents the most frequently occurring AEs in
implanted study eyes and in nonimplanted
fellow eyes in each of the implant dose groups
and combined. Among the most frequently
observed ocular AEs reported for implanted
study eyes, elevated IOP and cataract are
commonly associated with ocular steroid use.
Other frequently reported AEs in implanted
eyes (e.g., eye pain, hypotony, conjunctival
hemorrhage, and hyperemia) appear to be
primarily associated with surgery. In fellow
eyes, the most frequently observed ocular AEs
(decreased visual acuity, cataract formation,
and eye pain) were in part due to uveitic
inflammation experienced when the effects of
Fig. 2 Change in best-corrected visual acuity from base-
line up to 3 years post-implantation in the 0.59- and 2.1-
mg implant groups. A negative value represents an
improvement (P values from paired t test). *P\0.0001.
P = 0.0007. logMAR logarithm of the minimum angle
resolution, VA visual acuity
Fig. 3 Proportion of eyes with an improvement (left panel)
or deterioration (right panel) in visual acuity from baseline
of at least 0.30 logMAR at 3 years in the 0.59- and 2.1-mg
implant groups. (P values for the within-treatment
comparison of study eye versus fellow eye). *P\0.0001.
P = 0.0046. logMAR logarithm of the minimum angle
resolution
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periocular corticosteroid injections were below
therapeutic levels.
The FA implant was explanted from 19 eyes
(n = 5, 0.59-mg implant; n = 14, 2.1-mg implant)
over the course of the 3-year post-implantation
period. Seven implants were removed in the first
post-implantation year, eight in the second post-
implantation year, and four in the third post-
implantation year. The two most common
reasons attributed to these explants were
elevated IOP despite maximal medical therapy
(n = 2, 0.59-mg implant; n = 3, 2.1-mg implant)
and hypotony associated with implant wound
site leaks (n = 2, each implant dose). Other
reasons for explantation, all occurring in the
2.1-mg implant group, included implant wound
complication (n = 1), evisceration (n = 1),
endophthalmitis (n = 1), implant protrusion
(n = 3), uncontrolled glaucoma (n = 1), scleral
necrosis (n = 1), scleral melt (n = 1), and retinal
detachment (n = 1).
Intraocular Pressure
Table 7 presents the proportion of implant eyes
and fellow eyes with IOP elevations C10 mm Hg
at any time over the 3-year post-implantation
period. The highest proportion of study eyes
with IOP elevations C10 mm Hg in the 0.59-
and the 2.1-mg FA implant groups [31.3% (35/
112) and 37.8% (45/119), respectively] was seen
during the 1-year post-implantation visit;
thereafter, these proportions decreased
throughout the remaining months of follow-
up. The difference between implanted eyes and
fellow eyes during the 3 years of follow-up were
significant for both doses (P\0.001); however,
the differences between doses for implanted
eyes were not significant (P = 0.4229).
Cases of hypotony, defined as IOP\6 mm
Hg, were observed. In the 0.59-mg implant
group, 40.2% (47/117) of implanted eyes
experienced hypotony at sometime during the
3-year follow-up period compared to 17.9% (21/
117) of the fellow nonimplanted eyes
(P = 0.0002). In the 2.1-mg implant group,
hypotony occurred in 61.5% (75/122) of
implanted eyes during the 3-year follow-up
period compared to 16.9% (20/118) of the
fellow nonimplanted eyes (P\0.0001). The
difference between eyes treated with the 0.59-
and the 2.1-mg implants was significant
(P = 0.0007). Most instances of hypotony
occurred shortly after the implantation surgery
or IOP-lowering surgery.
Lens Opacification
The rate of C2-grade changes in lens opacities
from baseline for subcapsular, nuclear, and
Table 5 Number of patients experiencing reduction in the area of CME between baseline and the 3-year post-implantation
visit
Implant dose Implanted eyes Nonimplanted eyes P valuea
N Eyes experiencing
reduction in CME, n (%)
N Eyes experiencing
reduction in CME, n (%)
0.59 mg 50 38 (76.0) 50 14 (28.0) \0.0001
2.1 mg 48 30 (62.5) 48 6 (12.5) \0.0001
All 98 68 (69.4) 98 20 (20.4) \0.0001
CME cystoid macular edema
a P values were calculated via the McNemar test
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cortical lens regions were evaluated using the
LOCS II scale. Overall, C2-grade increases in
subcapsular lens opacity were observed in
57.6% (76/132) of phakic implanted eyes (both
dose groups combined) compared to 16.3% (26/
160) of phakic nonimplanted fellow eyes 3 years
post-implantation(P\0.0001). Lens opacity
increases in nuclear and cortical segments
were observed in 23.1% (27/117) and 22.8%
(26/114) of phakic implanted eyes, respectively
(both dose groups combined), by 3 years post-
implantation compared to 8.5% (13/153) and
9.5% (14/148), respectively, in the fellow
nonimplanted eyes.
Over the 3-year post-implantation follow-up
period, 94.9% (129/136) of phakic implanted
Table 6 Most frequently occurring ocular adverse events
Preferred terma Implant dose, N5 239
0.59-mg, n (%) 2.1-mg, n (%) All, n (%)
Study eye
Intraocular pressure increased 82 (70.1) 82 (67.2) 164 (68.6)
Eye pain 60 (51.3) 63 (51.6) 123 (51.5)
Visual acuity reduced 52 (44.4) 60 (49.2) 112 (46.9)
Conjunctival hemorrhage 42 (35.9) 54 (44.3) 96 (40.2)
Postoperative wound complication NOS 43 (36.8) 52 (42.6) 95 (39.8)
Conjunctival hyperemia 49 (41.9) 41 (33.6) 90 (37.7)
Cataract NOS 42 (35.9) 34 (27.9) 76 (31.8)
Cataract NOS aggravated 37 (31.6) 39 (32.0) 76 (31.8)
Hypotony of the eye 29 (24.8) 47 (38.5) 76 (31.8)
Abnormal sensation in the eye 31 (26.5) 35 (28.7) 66 (27.6)
Fellow eye
Visual acuity reduced 27 (23.1) 32 (26.2) 59 (24.7)
Cataract NOS aggravated 27 (23.1) 31 (25.4) 58 (24.3)
Eye pain 24 (20.5) 29 (23.8) 53 (22.2)
Intraocular pressure increased 28 (23.9) 18 (14.8) 46 (19.3)
Cataract NOS 20 (17.1) 21 (17.2) 41 (17.2)
Conjunctival hyperemia 18 (15.4) 15 (12.3) 33 (13.8)
Vitreous ﬂoaters 11 (9.4) 22 (18.0) 33 (13.8)
Vision blurred 14 (12.0) 16 (13.1) 30 (12.6)
Macular edema 14 (12.0) 15 (12.3) 29 (12.1)
Posterior capsule opaciﬁcation 11 (9.4) 14 (11.5) 25 (10.5)
NOS not otherwise speciﬁed
a Medical dictionary for regulatory activities (MedDRA) preferred nomenclature
Ophthalmol Ther (2015) 4:1–19 13
eyes (both doses combined) had cataract surgery
compared to 30.4% (51/168) of phakic
nonimplanted fellow eyes. Most of the cataract
surgeries in implanted eyes occurred between
1 year and 18 months post-implantation.
Visual Fields
Visual field sensitivity was quantified as the
mean deficit (MD), measured in decibels (dB).
At 3 years post-implantation, MD decreased by
0.47 dB in the 2.1-mg implant group and
improved by 0.35 dB in the 0.59-mg implant
group (P = 0.3967). There were no statistically
significant within-group changes in MD for
study or fellow eyes for each dose group and
for both dose groups combined. In the 0.59-mg
implant group, 9.8% (10/102) of implanted eyes
had a C10-dB reduction in MD at any time
during the 3-year post-implantation follow-up
period compared to 3.9% (4/102) in the fellow
nonimplanted eyes (P = 0.001). In the 2.1-mg
implant group, 16.0% (17/106) of implanted
eyes had a C10-dB reduction in MD at any time
during the 3-year post-implantation follow-up
period compared to 2.1% (2/96) in the fellow
nonimplanted eyes (P = 0.001). There were no
statistically significant differences between
treatments.
Nonocular Adverse Events
Nonocular AEs were reported in 86.6% (207/
239) of patients in both dose groups combined.
The most frequently observed nonocular AEs
were headache [29.3% (70/239)],
nasopharyngitis [17.2% (41/239)], arthralgia
[16.3% (39/239)], and pyrexia [15.1% (36/239)].
Over the course of the study, three patients
died: one in the 0.59-mg implant group
(abdominal aortic aneurysm) and two in the
2.1-mg implant group (sudden cardiac arrest,
pneumonia). None of the deaths was related to
the study drug.
DISCUSSION
The results of this study demonstrate that the
FA intravitreal implant is effective in the
treatment of NIPU in a predominantly Asian
patient population. The FA intravitreal implant
effectively reduced rates of uveitis recurrence
and improved visual outcomes compared to
nonimplanted fellow eyes. The degree of
Table 7 Incidence of intraocular pressure increase of C10 mm Hg from baseline over the 3-year post-implantation period
Time (months) 0.59-mg Implant 2.1-mg Implant
Study eyes Fellow eyes Study eyes Fellow eyes
N Incidence Percent N Incidence Percent N Incidence Percent N Incidence Percent
6 113 25 22.1 111 2 1.8 119 34 28.6 115 7 6.1
12 112 35 31.3 109 4 3.7 119 45 37.8 115 6 5.2
18 109 24 22.0 108 3 2.8 115 28 24.3 111 3 2.7
24 107 17 15.9 106 1 0.9 110 23 20.9 106 5 4.7
30 102 18 17.6 100 8 8.0 110 15 13.6 108 5 4.6
36 103 12 11.7 101 1 1.0 106 9 8.5 105 6 5.7
Overall 115 78 67.8 114 24 21.1 122 87 71.3 118 22 18.6
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improvement relative to the nonimplanted
fellow eyes was especially notable given that
most patients had bilateral NIPU and had the
more severely affected eye implanted. Uveitis
recurrence rates in eyes treated with the FA
intravitreal implant (combined dose groups)
decreased from 42.3% during the 1-year pre-
implantation period to 25.9% during the 3-year
post-implantation period, and control was
maintained through 3 years. Visual acuity in
implanted eyes was stabilized or improved in
80% of eyes with a significant number of eyes
demonstrating a C3 line improvement at
3 years post-implantation. Furthermore, eyes
treated with the FA intravitreal implant had a
reduced need for adjunctive systemic therapy or
periocular or topical corticosteroid injections to
control uveitis. These data are consistent with
two previous studies evaluating the FA
intravitreal implant in the treatment of NIPU
[18, 20]. Both the marketed 0.59-mg FA
intravitreal implant (Retisert) and the 2.1-mg
FA intravitreal implant demonstrated similar
efficacy, although the higher-dose implant
tended to have a shorter time to uveitis
recurrence. This was attributed to a shorter
lifespan of the 2.1-mg implant and consistent
with known in vitro release rate data, suggesting
that the drug reservoir is depleted more rapidly
in the higher-dose implant.
The main cause of visual loss in patients with
posterior uveitis is CME [21, 22]. The ability of
the FA implant to reduce CME through control
of inflammation led to good visual acuity
outcomes. These improved visual acuity
outcomes were observed despite the formation
of cataracts in the majority of implanted
patients. Cataract formation and progress are
common in eyes with uveitis and attributable
both to the inflammatory progress and to the
chronic use of corticosteroids to control the
disease. [16] In this study, nearly all (94.9%)
implanted phakic eyes underwent cataract
surgery during the 3-year follow-up with a
high incidence of reduction in BCVA of C3
lines observed between 12 and 18 months post-
implantation—the period during follow-up
when most cataract surgeries were performed
in implanted eyes. However, following cataract
removal, implant eye visual acuity improved,
with a significant improvement in mean BCVA
compared with baseline in the 0.59-mg implant
group at 2 and 3 years post-implantation and
with 27.4% of implanted eyes (both dose groups
combined) improved by C3 lines over baseline
at 3 years post-implantation, a significantly
greater proportion than that observed in
fellow nonimplanted eyes (P\0.0001).
Notably, in a follow-up post hoc analysis of
post-surgical outcomes in eyes requiring
cataract extraction from an earlier Phase II/III
study of the FA implant in the treatment of
NIPU, Sheppard et al. [23] reported better vision
and less intraocular inflammation following
cataract surgery in implanted eyes compared
with nonimplanted eyes. These results were
more remarkable, in that in the study, as well as
in the current study, the FA-implanted eye
represented each patient’s worse eye. At 1 and
3 months post-cataract extraction, mean
improvement in visual acuity was significantly
greater in implanted than nonimplanted eyes
(P B 0.0047) and significantly fewer AC cells
were seen in implanted than nonimplanted
eyes (P B 0.0084) [23].
Elevated IOP is also common in uveitic eyes
due to the occlusion of aqueous outflow by
inflammatory debris and/or formation of
peripheral anterior synechia [24, 25]. Herbert
et al. [26] reported the prevalence of elevated
IOP in uveitis patients to be as high as 41.8%;
with 29.8% of cases requiring treatment to
manage the elevated IOP. The proportion of
implanted eyes experiencing elevations in IOP
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in this studywashigher (67.8%and71.3%of eyes
in the 0.59- and the 2.1-mg implant groups,
respectively), due to the fact that corticosteroid
treatment itselfmay also lead to reduced aqueous
outflowthroughavarietyofmechanisms [27,28].
While the majority of implanted eyes with IOP
elevations were successfully treated with IOP-
lowering medications, 33% of implanted eyes
with IOP elevations required glaucoma-filtering
procedures to control IOP. Details of the topical
IOP-lowering medications and filtering
procedures utilized in this study and the two
previous FA implant studies have been described
by Goldstein et al. [29]. Trabeculectomy was the
most common surgical procedure in this and
previous studies, and surgical procedures were
deemed successful in 85.1% of eyes at 1 year
(postoperative IOP of 6–21 mm Hg with or
without additional IOP-lowering medication).
As might be expected, there were more
ocular AEs in implanted eyes compared with
nonimplanted fellow eyes. Adverse events in
nonimplanted eyes appeared to be reflective, in
large part, of the underlying uveitic process
(e.g., reduced visual acuity, cataract, eye pain,
increased IOP, conjunctival hyperemia, vitreous
floaters, blurred vision, macular edema), while
AEs in implanted eyes were consistent with the
surgical procedure and corticosteroid delivered
(e.g., increased IOP, eye pain, conjunctival
hermorrhage, postoperative wound
complications, cataract formation). Notably,
there were no nonocular AEs considered
treatment related in either implant group. This
finding is likely due to the negligible systemic
exposure to FA following implantation of the FA
implant. In a previous study of patients who
received the intravitreal implant, and had blood
samples taken at various times after
implantation, plasma levels of FA were below
the limit of detection [30].
The dose-controlled design of this study,
along with the lack of randomization regarding
the treatment eye in bilateral cases, precludes
definitive distinction from regression to the
mean as the explanation for the apparent
treatment effects on many of the clinical
findings, including visual acuity and recurrent
inflammation. The biologic plausibility and
magnitude of the results, however, suggest
that treatment effects were the primary
contributor to the results.
CONCLUSION
The results of this study demonstrate the
efficacy of the FA intravitreal implant in the
treatment of NIPU in a population of
predominantly Asian patients. The FA
intravitreal implant led to both significant
reductions in uveitis recurrence rates and
improvements in visual acuity. Elevated IOP
and cataract formation were the most common
AEs, consistent with the natural history of the
disease and the treatment used. Unlike previous
studies, there were more complications related
to implant site wound leaks. It is therefore
especially important that the physician pays
careful attention to wound closure in the
uveitic patient treated with an FA implant.
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